Plans unveiled for new MS drug study for Cyrevia
Plans unveiled for new MS drug study for Cyrevia
The leading physicians from Accentia Biopharmaceuticals, Inc. and Johns Hopkins University have presented plans for a randomized clinical trial to study Cyrevia (formerly Revimmune) in multiple sclerosis (MS) to a number of key opinion leaders in the field and potential site investigators. Johns Hopkins University will serve as the lead trial site for the study.
Physicians also co-hosted a meeting with prospective clinical trial investigators at the recent American Academy of Neurology (AAN) Annual Meeting in New Orleans.
A group of invited key opinion leaders and neurologists from leading Multiple Sclerosis Centres of Excellence attended the Cyrevia investigators meeting, hearing presentations from two Johns Hopkins physicians: Douglas E Gladstone, MD, associate professor of Oncology, clinical director in-patient/out-patient programme (IPOP), Sidney Kimmel Comprehensive Cancer Centre; and Daniel M Harrison, MD, assistant professor of Neurology. Drs Gladstone and Harrison reviewed multiple open-label phase II Cyrevia studies conducted at Johns Hopkins, demonstrating significant benefit for Cyrevia versus historical outcomes in the treatment of a range of autoimmune diseases, and jointly proposed a controlled, randomized, multi-centre phase III MS study.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2018
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 479 Views
-
Last post by NHE
-
- 0 Replies
- 1589 Views
-
Last post by NHE
-
- 1 Replies
- 3042 Views
-
Last post by Tif
-
- 2 Replies
- 955 Views
-
Last post by DIM
-
- 1 Replies
- 1884 Views
-
Last post by raceya
-
- 0 Replies
- 2080 Views
-
Last post by DIM
-
- 0 Replies
- 1629 Views
-
Last post by frodo
-
- 0 Replies
- 1912 Views
-
Last post by DIM
-
- 0 Replies
- 1953 Views
-
Last post by Tif